| abstract |
Novel [(Bicyclic heterocyclyl)methyl and -hetero] substituted hexahydro-1H-azepines and pyrrolidines of formula <CHEM> wherein -A<1>=A<2>-A<3>=A<4>- is -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N-, -N=CH-N=CH-, or -CH=N-CH=N-, R<1> is hydrogen, C1-10alkyl, C3-6cycloalkyl, Ar<1> or C1-6alkyl substituted with one or two Ar<1> radicals; B is NR<2>, CH2, O, S, SO or SO2; R is hydrogen or C1-6alkyl; n is 0 or 2; L is hydrogen, C1-6alkylcarbonyl, C1-6alkylsulfonyl, C1-6alkyloxycarbonyl, Ar<2>-C1-6alkyloxycarbonyl, Ar<2>-carbonyl, Ar<2>-sulfonyl, C3-6cycloalkyl, C2-6alkenyl optionally substituted with Ar<2>, C1-12alkyl, a radical of formula -Alk-R<3>, -Alk-Y-R<4>, -Alk-Z<1>-C(X)-Z<2>-R<5>, or -CH2-CHOH-CH2-O-R<6>; the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof, which compounds are anti-allergic agents; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions. |